These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 37195310)

  • 21. The pharmacogenomics of selective serotonin reuptake inhibitors.
    García-Marín LM; Rabinowitz JA; Ceja Z; Alcauter S; Medina-Rivera A; Rentería ME
    Pharmacogenomics; 2022 Jul; 23(10):597-607. PubMed ID: 35673953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenomics with antidepressants in the STAR*D study.
    Lin E; Chen PS
    Pharmacogenomics; 2008 Jul; 9(7):935-46. PubMed ID: 18597655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delineating significant genome-wide associations of variants with antipsychotic and antidepressant treatment response: implications for clinical pharmacogenomics.
    Koromina M; Koutsilieri S; Patrinos GP
    Hum Genomics; 2020 Jan; 14(1):4. PubMed ID: 31941550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacogenetic considerations for late life depression therapy.
    Pitychoutis PM; Kokras N; Sanoudou D; Dalla C; Papadopoulou-Daifoti Z
    Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):989-99. PubMed ID: 23641676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenetics of antidepressant drugs: current clinical practice and future directions.
    Narasimhan S; Lohoff FW
    Pharmacogenomics; 2012 Mar; 13(4):441-64. PubMed ID: 22380000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology.
    Ross CJ; Visscher H; Sistonen J; Brunham LR; Pussegoda K; Loo TT; Rieder MJ; Koren G; Carleton BC; Hayden MR;
    Thyroid; 2010 Jul; 20(7):681-7. PubMed ID: 20578893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene-drug pairings for antidepressants and antipsychotics: level of evidence and clinical application.
    Murphy LE; Fonseka TM; Bousman CA; Müller DJ
    Mol Psychiatry; 2022 Jan; 27(1):593-605. PubMed ID: 34754108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetika+: precision medicine solutions for mental health.
    Albeldas C; Cohen N; Natan S; Askari N; Laifenfeld D; Solal TC
    Pharmacogenomics; 2022 Jul; 23(10):571-574. PubMed ID: 35880563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospects for personalization of depression treatment with genome sequencing.
    Borczyk M; Piechota M; Rodriguez Parkitna J; Korostynski M
    Br J Pharmacol; 2022 Sep; 179(17):4220-4232. PubMed ID: 33786859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacogenomics and Personalized Medicine.
    Cecchin E; Stocco G
    Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32580376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Efficacies and Toxicities of Antidepressant Drugs in Clinics, Building the Relationship between Chemo-Genetics and Socio-Environments.
    Lu DY; Lu TR; Zhu PP; Che JY
    Cent Nerv Syst Agents Med Chem; 2015; 16(1):12-8. PubMed ID: 25924829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The search for personalized antidepressant treatments: what have we learned and where are we going.
    Serretti A; Fabbri C
    Pharmacogenomics; 2020 Oct; 21(15):1095-1100. PubMed ID: 33016213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetics of antidepressant response and treatment-resistant depression.
    Chung AN; Chen TT; Lin YF
    Prog Brain Res; 2023; 278():25-60. PubMed ID: 37414493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Personalized Medicine: Pharmacogenomics and Drug Development.
    Mirsadeghi S; Larijani B
    Acta Med Iran; 2017 Mar; 55(3):150-165. PubMed ID: 28282716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical validation of a combinatorial PharmAcogeNomic approach in major Depressive disorder: an Observational prospective RAndomized, participant and rater-blinded, controlled trial (PANDORA trial).
    Minelli A; Barlati S; Vitali E; Bignotti S; Dattilo V; Tura GB; Maffioletti E; Giacopuzzi E; Santoro V; Perusi G; Cobelli C; Magri C; Bonizzato S; Bocchio-Chiavetto L; Spina E; Vita A; Gennarelli M
    Trials; 2021 Dec; 22(1):896. PubMed ID: 34895291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Role of Pharmacogenetics in Personalizing the Antidepressant and Anxiolytic Therapy.
    Radosavljevic M; Svob Strac D; Jancic J; Samardzic J
    Genes (Basel); 2023 May; 14(5):. PubMed ID: 37239455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenetic Implications for Antidepressant Pharmacotherapy in Late-Life Depression: A Systematic Review of the Literature for Response, Pharmacokinetics and Adverse Drug Reactions.
    Marshe VS; Islam F; Maciukiewicz M; Bousman C; Eyre HA; Lavretsky H; Mulsant BH; Reynolds CF; Lenze EJ; Müller DJ
    Am J Geriatr Psychiatry; 2020 Jun; 28(6):609-629. PubMed ID: 32122803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of pharmacogenomics in elderly patients treated for cardiovascular diseases.
    Božina N; Vrkić Kirhmajer M; Šimičević L; Ganoci L; Mirošević Skvrce N; Klarica Domjanović I; Merćep I
    Croat Med J; 2020 Apr; 61(2):147-158. PubMed ID: 32378381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacogenomics and adverse drug reactions: Primetime and not ready for primetime tests.
    Khan DA
    J Allergy Clin Immunol; 2016 Oct; 138(4):943-955. PubMed ID: 27720019
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.